Construction materials supplier CRH cleared a buy point Thursday after announcing plans to unload its stake in SigmaRoc.

Samsara is the IBD Stock of the Day ahead of its Q4 earnings report due March 6. Samara stock has forged a cup base, rebounding from a sell-off.

Despite advances in treatment for inflammatory bowel disease, more than 55% of patients report medication delays, mostly due ...

Brady Cl A saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, rising from 68 to 72. Please watch the ...

In terms of fundamentals, Omnicell has posted three quarters of increasing earnings growth. Revenue growth has also moved ...

For older adults with inflammatory bowel disease (IBD), there was no significant difference in the risk of major ...

A study led by the University of Birmingham found that vancomycin, a commonly used antibiotic for diarrhea, could effectively ...

The inflammatory bowel disease (IBD), develops due to an incurable autoimmune liver disease called primary sclerosing ...

A recent major OECD report has warned of a looming crisis in the European health workforce. In the third in our series on the ...

Researchers from The Institute of Cancer Research in London have developed a new test that can predict colorectal cancer risk ...

IBD Aware, a wearable medical device in development for patients with inflammatory bowel disease, aims to improve disease ...

Trial showed promising results for patients with IBD and autoimmune liver disease with 80% achieving clinical remission ...